Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 16, 2017. The document serves as a transaction notification reporting share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with the company.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Transaction Type | Price per Share | Exchange |
|---|---|---|---|---|
| January 12, 2017 | Ordinary Shares (25p each) | Acquisition via Dividend Re-investment | £15.7149 | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine share acquisitions by eleven individuals (including the CEO, CFO, and other senior executives) resulting from the re-investment of dividends paid on January 12, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment plans, not open market purchases or sales.
- Participants: Transactions involved senior leadership including Sir Andrew Witty (CEO), Ms E Walmsley (CEO Designate), and Mr S Dingemans (CFO).
- Share Price: The uniform transaction price was £15.7149 per share.
- Volume: Individual share volumes varied significantly, ranging from 0.005 shares (Ms E Walmsley) to 1,693.943 shares (Dr P J T Vallance).
- Corporate Data: The filing does not contain updated financial statements or operational results for the period.